Joanne Wuu
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
Koch J, Leha A, Bidner H, Cordts I, Dorst J, Günther R, Zeller D, Braun N, Metelmann M, Corcia P, Depla E, Weydt P, Meyer T, Grosskreutz J, Soriani M, Attarian S, Weishaupt J, Weyen U, Kuttler J, Zurek G, Rogers M, Feneberg E, Deschauer M, Neuwirth C, Wuu J, Ludolph A, Schmidt J, Remane Y, Camu W, Friede T, Benatar M, Weber M, Lingor P, ROCK-ALS Study group. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2024; 23:1133-1146.
Nov 1, 2024Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
Nov 1, 2024Lancet Neurol 2024; 23:1133-1146
Koch Jan Christoph, Leha Andreas, Bidner Helen, Cordts Isabell, Dorst Johannes, Günther René, Zeller Daniel, Braun Nathalie, Metelmann Moritz, Corcia Philippe, Depla Erik, Weydt Patrick, Meyer Thomas, Grosskreutz Julian, Soriani Marie-Hélène, Attarian Shahram, Weishaupt Jochen H, Weyen Ute, Kuttler Josua, Zurek Gabriela, Rogers Mary-Louise, Feneberg Emily, Deschauer Marcus, Neuwirth Christoph, Wuu Joanne, Ludolph Albert C., Schmidt Jens, Remane Yvonne, Camu William, Friede Tim, Benatar Michael, Weber Markus, Lingor Paul, ROCK-ALS Study group
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist M, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg L, Juntas-Morales R, Chio A, Andersen P, Pradat P, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal N, Meyer T, Hanna M, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph A, Neuwirth C, Nations S, Shefner J, Turner M, Wuu J, Bennett R, Dang H, Sundgreen C, ORARIALS-01 trial team. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Neurol 2024; 23:687-699.
May 20, 2024Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
May 20, 2024Lancet Neurol 2024; 23:687-699
Benatar Michael, Hansen Thomas, Rom Dror, Geist Marie A, Blaettler Thomas, Camu William, Kuzma-Kozakiewicz Magdalena, van den Berg Leonard H, Juntas-Morales Raul, Chio Adriano, Andersen Peter Munch, Pradat Pierre-Francois, Lange Dale J, Van Damme Philip, Mora Gabriele, Grudniak Mariusz, Elliott Matthew, Petri Susanne, Olney Nicholas, Ladha Shafeeq S, Goyal Namita A, Meyer Thomas, Hanna Michael G, Quinn Colin, Genge Angela, Zinman Lorne, Jabari Duaa, Shoesmith Christen, Ludolph Albert C., Neuwirth Christoph, Nations Sharon, Shefner Jeremy M, Turner Martin R, Wuu Joanne, Bennett Richard, Dang Hoang, Sundgreen Claus, ORARIALS-01 trial team
Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations
Lingor P, Tostmann R, Neuwirth C, Meyer T, Lengenfeld T, Leha A, Kuttler J, Kollewe K, Kassubek J, Ilse B, Günther R, Ahmed R, Langbein T, Wuu J, Hennecke C, Hussain S, Statland J, Koch J, Benatar M. Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations. Amyotroph Lateral Scler Frontotemporal Degener 2021; 22:419-425.
Feb 3, 2021Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations
Feb 3, 2021Amyotroph Lateral Scler Frontotemporal Degener 2021; 22:419-425
Lingor Paul, Tostmann Ralf, Neuwirth Christoph, Meyer Thomas, Lengenfeld Teresa, Leha Andreas, Kuttler Josua, Kollewe Katja, Kassubek Jan, Ilse Benjamin, Günther René, Ahmed Raees, Langbein Thomas, Wuu Joanne, Hennecke Christiane, Hussain Sumaira, Statland Jeffrey M, Koch Jan C, Benatar Michael
Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study
Nordin A, Burkhardt C, Neuwirth C, Holmøy T, Morita M, Tysnes O, Benatar M, Wuu J, Lange D, Bisgård C, Asgari N, Tarvainen I, Brännström T, Weber M, Schweikert K, Grehl T, Akimoto C, Wuolikainen A, Alstermark H, Forsberg K, Baumann P, Pinto S, de Carvalho M, Hübers A, Nordin F, Ludolph A, Weishaupt J, Meyer T, Andersen P. Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotroph Lateral Scler Frontotemporal Degener 2016; 18:256-264.
Dec 12, 2016Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study
Dec 12, 2016Amyotroph Lateral Scler Frontotemporal Degener 2016; 18:256-264
Nordin Angelica, Burkhardt Christian, Neuwirth Christoph, Holmøy Trygve, Morita Mitsuya, Tysnes Ole-Bjørn, Benatar Michael, Wuu Joanne, Lange Dale J, Bisgård Carsten, Asgari Nasrin, Tarvainen Ilkka, Brännström Thomas, Weber Markus, Schweikert Kathi, Grehl Torsten, Akimoto Chizuru, Wuolikainen Anna, Alstermark Helena, Forsberg Karin, Baumann Peter, Pinto Susana, de Carvalho Mamede, Hübers Annemarie, Nordin Frida, Ludolph Albert C, Weishaupt Jochen H, Meyer Thomas, Andersen Peter M